118 related articles for article (PubMed ID: 1615925)
1. DNA analysis to aid in the diagnosis of chronic myeloproliferative disorders.
Kreipe H; Felgner J; Jaquet K; Heidorn K; Radzun HJ; Parwaresch R
Am J Clin Pathol; 1992 Jul; 98(1):46-54. PubMed ID: 1615925
[TBL] [Abstract][Full Text] [Related]
2. [Histopathology and molecular pathology of chronic myeloproliferative disorders].
Kreipe HH
Veroff Pathol; 1993; 141():1-158. PubMed ID: 8372486
[TBL] [Abstract][Full Text] [Related]
3. Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders.
Pastore C; Nomdedeu J; Volpe G; Guerrasio A; Cambrin GR; Parvis G; Pautasso M; Daglio C; Mazza U; Saglio G
Genes Chromosomes Cancer; 1995 Oct; 14(2):106-11. PubMed ID: 8527391
[TBL] [Abstract][Full Text] [Related]
4. Increased incidence of monoclonal B-cell infiltrate in chronic myeloproliferative disorders.
Pajor L; Lacza A; Kereskai L; Jáksó P; Egyed M; Iványi JL; Radványi G; Dombi P; Pál K; Losonczy H
Mod Pathol; 2004 Dec; 17(12):1521-30. PubMed ID: 15257312
[TBL] [Abstract][Full Text] [Related]
5. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
6. Evidence from molecular genetic and cytogenetic analyses that bone marrow histopathology is reliable in the diagnosis of chronic myeloproliferative disorders.
Werner M; Kaloutsi V; Kausche F; Buhr T; Georgii A
Virchows Arch B Cell Pathol Incl Mol Pathol; 1993; 63(4):199-204. PubMed ID: 8099457
[TBL] [Abstract][Full Text] [Related]
7. Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders.
Bock O; Büsche G; Koop C; Schröter S; Buhr T; Kreipe H
J Mol Diagn; 2006 May; 8(2):170-7. PubMed ID: 16645202
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of tumor progression in chronic myeloproliferative disorders.
Gaidano G; Guerrasio A; Serra A; Rege-Cambrin G; Saglio G
Leukemia; 1994 Apr; 8 Suppl 1():S27-9. PubMed ID: 8152300
[TBL] [Abstract][Full Text] [Related]
9. Mutations in the P53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders.
Gaidano G; Guerrasio A; Serra A; Carozzi F; Cambrin GR; Petroni D; Saglio G
Leukemia; 1993 Jul; 7(7):946-53. PubMed ID: 8321046
[TBL] [Abstract][Full Text] [Related]
10. bcr gene rearrangement analysis in myeloproliferative disorders other than chronic myelogenous leukemia.
Crisan D; Mattson JC; O'Malley BA; Schulz RW; Wilner F
Cancer Detect Prev; 1996; 20(4):263-9. PubMed ID: 8818385
[TBL] [Abstract][Full Text] [Related]
11. [Detection of BCR/ABL fusion gene by fluorescence in situ hybridization and its clinical application].
Zhou RL; Mo YX; Lan M; Lin JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1283-8. PubMed ID: 22040989
[TBL] [Abstract][Full Text] [Related]
12. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
13. p190 bcr-abl rearrangement: a secondary cytogenetic event in some chronic myeloid disorders?
Roumier C; Daudignon A; Soenen V; Dupriez B; Wetterwald M; Lai JL; Cosson A; Fenaux P; Preudhomme C
Haematologica; 1999 Dec; 84(12):1075-80. PubMed ID: 10586207
[TBL] [Abstract][Full Text] [Related]
14. Karyotype findings and molecular analysis of the bcr gene rearrangement supplementing the histologic classification of chronic myeloproliferative disorders.
Werner M; Nolte M; Kaloutsi V; Buhr T; Kausche F; Georgii A
Lab Invest; 1995 Apr; 72(4):405-10. PubMed ID: 7723278
[TBL] [Abstract][Full Text] [Related]
15. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
[TBL] [Abstract][Full Text] [Related]
16. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
17. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.
Mesa RA
Int J Hematol; 2002 Aug; 76 Suppl 2():193-203. PubMed ID: 12430925
[TBL] [Abstract][Full Text] [Related]
18. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
19. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia.
Lin P; Jones D; Medeiros LJ; Chen W; Vega-Vazquez F; Luthra R
Am J Clin Pathol; 2006 Oct; 126(4):530-3. PubMed ID: 16938665
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid disorders: Classification and treatment overview.
Tefferi A
Semin Hematol; 2001 Jan; 38(1 Suppl 2):1-4. PubMed ID: 11242595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]